Novo Nordisk spells out the details behind a PhII NASH failure which reshaped its clinical plans

A little more than a year after Novo Nordisk and Gilead agreed to push into bigger studies of a 3-drug combo in NASH, the Danish pharma has spelled out the data after running into a fresh obstacle on the monotherapy prospects for their big drug semaglutide — branded as Ozempic…

...

Click to view original post